Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, January 2000, p. 79-85, Vol. 7, No. 1
Department of
Otolaryngology1 and Department of
Pediatrics,2 Long Island Jewish Medical Center,
The Long Island Campus for the Albert Einstein College of Medicine, New
Hyde Park, New York 11040
Received 30 April 1999/Returned for modification 24 June
1999/Accepted 18 October 1999
Recurrent respiratory papillomatosis (RRP) is an insidious disease
caused by human papillomavirus (HPV) infection. It is characterized by
a variable clinical course that can include frequent disease recurrence, significant morbidity, and occasional mortality. The mechanisms responsible for the variability in the clinical course and
the persistence of latent HPV infection remain unknown. Effective T-cell-mediated clearance of HPV-infected cells may be defective in
patients with RRP, leading to recurrent disease and failure to suppress
latent HPV reactivation. This study describes the down-regulation of
the transporter associated with antigen presentation (TAP-1) and the
major histocompatibility complex (MHC) class I protein expression in
laryngeal papilloma tissue biopsies and cell culture of primary
explants. There was a statistically significant correlation between
reduction of TAP-1 expression in biopsy tissues and rapid recurrence of
disease. Patients with RRP had less frequent recurrence if their
papillomas expressed TAP-1 at levels close to that of normal tissue,
compared with those with very low expression of TAP-1, who had frequent
recurrence (32 versus 5 weeks to the next surgical intervention). These
findings suggest that HPV may evade immune recognition by
down-regulating class I MHC cell surface expression via decreased TAP-1
levels. Expression of TAP-1 could be used for prognostic evaluation of
disease severity. Gamma interferon was able to restore class I MHC
expression at the surfaces of laryngeal papilloma cells in culture.
This up-regulation of class I MHC antigen at the cell surface
potentially allows the infected cell to become a target for the immune
system again. This finding provides some promise for nonsurgical
treatment of laryngeal papillomas.
1071-412X/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Altered Expression of TAP-1 and Major
Histocompatibility Complex Class I in Laryngeal Papillomatosis:
Correlation of TAP-1 with Disease
*
Corresponding author. Mailing address: Dept. of
Otolaryngology, Long Island Jewish Medical Center, 270-05 76th Ave.,
New Hyde Park, NY 11040. Phone: (718) 470-7550. Fax: (718) 347-2320. E-mail: vambutas{at}lij.edu.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |